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Abstract
Background: Although multinational clinical trials frequently use patient-reported outcomes to measure
efficacy, measurement equivalence across cultures and languages, a scientific requirement, is rarely
tested. Clinically accessible accounts are rare; exemplars are needed.
Objective: To develop and test a Turkish version of the Multiple Sclerosis Walking Scale (MSWS-
12v2) as a clinical exemplar for examining measurement equivalence.
Methods: The MSWS-12v2 Turkish (MSWS-12v2T) was developed using recognised methods for
linguistic equivalence. Rasch measurement theory was used to examine measurement performance
(multiple tests of targeting, scale performance, and person measurement) and measurement equivalence
(differential item functioning). UK data (n¼ 3310) were used for comparisons and differential item
functioning testing.
Results: One hundred and twenty-four people from two Turkish centres completed the MSWS-12v2T.
Rasch measurement theory evidence supported MSWS-12v2T as reliable (person separation¼ 0.96)
and valid (thresholds ordered; no concerning item misfit, bias, or person misfit). However, four items
demonstrated significantly different performance between UK and Turkish samples. These item
differences significantly affected scores (person measurements) at the group-level (p< 0.001).
Individual person differences were less pronounced.
Conclusions: Linguistic equivalence does not guarantee measurement equivalence; independent testing
is required. Rasch measurement theory enables sophisticated and unique examinations of cross-cultural
measurement equivalence and we recommend this be tested routinely in pivotal multiple sclerosis
clinical trials.
Keywords: Rasch measurement theory, mobility limitation, cross-cultural evaluation, differential item
functioning, Multiple Sclerosis Walking Scale, psychometrics
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Introduction
Clinical trials in multiple sclerosis (MS) and other
diseases are increasingly multinational and use
patient-reported outcome measures (PROs) to evalu-
ate efficacy.1 Obtaining clinically meaningful and
accurate conclusions from these trials require that
the measurement properties of PROs are stable
across cultures and languages.24 Here, we address
this significant task by developing and testing the 12-
item MS Walking Scale (MSWS-12) in a Turkish
version to provide a clinically accessible demonstra-
tion of process and discussion of requirements and
methods.
Typically, the PROs used in multinational studies
have been translated into relevant languages using
recognised methods that seek to achieve linguistic
equivalence,58 on the assumption that this equates
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to measurement equivalence, which is rarely
examined. However, while linguistic equivalence is
necessary, it is not comprehensive enough to dem-
onstrate measurement equivalence.14 PRO meas-
urement performance is a context-dependent
empirical question that requires formal comparisons
of psychometric properties in study data across vari-
ables that include language and versions.2 Moreover,
measurement stability in one context (e.g. English
language) does not guarantee measurement stability
in another (e.g. Turkish language).
Measurement equivalence can be studied with ‘trad-
itional’ and ‘modern’ psychometric methods.9
Clinicians are more familiar with the traditional
methods of reliability and validity testing, which
are based on classical test theory (CTT).a,10,11
Within this paradigm, similarity of PRO item and
scale parameters across different samples indicates
measurement stability.b However, results generated
by traditional psychometric methods are limited
because their statistical tests are score-distribution
dependent.10,11 Therefore, results are confounded
unless the groups compared have similar sample
mean scores and standard deviations (SDs). This
cannot be dictated within a clinical trial.
Modern psychometric methods, a general term embra-
cing two related but different paradigms called Rasch
measurement theory (RMT)12,13 and item response
theory (IRT),10 enable far more rigorous and sophis-
ticated evaluations of measurement equivalence than
CTT. First, both paradigms use mathematical models;
therefore, formal testing is conducted on the extent to
which observed data accord with, or ‘fit,’ the expect-
ations that were articulated mathematically. Second,
both paradigms enable examinations of differential
item functioning (DIF)  head-to-head comparisons
of item performance across groups.14 That being said,
RMT has unique advantages over IRT: item param-
eter estimates generated by RMT analyses are inde-
pendent from the distributional properties of the
sample from which they are derived.1519 While
results arising from the analysis of PRO data from a
sample must be sample-dependent to some extent,
RMT analyses allow for the meaningful comparisons
of item performance and scale performance stability
to be performed across groups with different distribu-
tions. This critical concept is fundamentally
important.
Here, we report the development, testing, and exam-
ination of measurement equivalence of a Turkish
version of the MSWS-12v2 (MSWS-12v2T) using




The study had three stages. First, we developed the
MSWS-12v2T using standard methods (stage 1:
translation and adaptation). Second, we administered
the MSWS-12v2T to a sample of Turkish people
with MS, and examined item responses using RMT
(stage 2: RMT examination of MSWS-12v2T
performance). Third, we examined the performance
stability of the MSWS-12v2T against the UK
MSWS-12v2 using data from the South West
Impact of MS study (SWIMS; stage 3: examination
of the performance stability of the MSWS-12v2T).20
All participants included in the study were aged 18
years or older, and gave their prior voluntary verbal
informed consent. Ethics approval from the
Institutional Review Board (IRB) was not required
for the Turkish aspects of this study. SWIMS was
approved by the local research ethics committee in
2004.20 RMT analyses were conducted using
RUMM2030 professional.21,22
MSWS-12v2 questionnaire
The MSWS-12v2 is a PRO questionnaire developed
to measure the impact of MS on walking.23 The
instrument has 12 questions (items) asking people
with MS to rate 12 different aspects of walking-
related tasks during the preceding two weeks. The
MSWS-12v1 was developed using traditional psycho-
metric methods; all items had five response categories
(1¼‘not at all’ to 5¼‘extremely’).24 However, RMT
examinations of MSWS-12v1 implied that three items
had too many response categories. Therefore, the
updated MSWS-12v2 questionnaire has three items
with three response categories (1¼‘not at all’;
2¼‘sometimes’; 3¼‘a lot’).23 The response categories
for the remaining nine items were unchanged. The
MSWS-12v2 questionnaire has been, and is currently
being, used in multiple clinical trials.25 The traditional
method of scoring the MSWS-12v2 is to summate
item scores to generate a total score between 1254.
Lower scores indicate improved walking disability.23
Stage 1: translation and adaptation
Two bi-lingual Turkish-English medically trained
doctors working for a professional translation
agency, independently, and without conferring,
translated the MSWS-12v2 into Turkish (forward
translation). The content and conceptual equivalence
of the two translated Turkish versions were
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compared. Differences were reconciled by two inde-
pendent doctors, one of whom was the lead author.
Finally, the Turkish version was translated back into
English by two blinded translators without previous
knowledge of the MSWS-12 (backward translation).
The two back-translated versions of the MSWS-12v2
questionnaire were compared with the original UK
MSWS-12v2 questionnaire. Differences were recon-
ciled by an independent medical doctor and the lead
author. The updated and translated MSWS-12v2T
questionnaire was approved by the authors.
Stage 2: RMT examination of MSWS-12v2T
performance
During 2012, the MSWS-12v2T was administered to
Turkish people with MS attending two outpatient
centres located in South Eastern Turkey (Dicle
University) and by the Black Sea (Samsun
University). Treating neurologists approached con-
secutive outpatient attendees verbally inviting them
to complete the questionnaire on the appointment
day. Data collection continued until approximately
125 completions were received. The sample size
was arbitrary and deemed adequate for the purpose.
MSWS-12v2T item responses were analysed using
RMT. Multiple analyses were conducted in three
broad areas: item and scale-to-sample targeting;
item and scale performance; person and group meas-
urement. These methods are described fully
elsewhere.9
Stage 3: examination of the performance stability of
the MSWS-12v2T
Three different analyses were undertaken to determine
the measurement stability of the MSWS-12v2T com-
pared with the original UK version. We used data
from SWIMS: a longitudinal cohort study of people
from two UK counties (Devon and Cornwall) with
neurologist-confirmed MS who complete multiple
PROs on a six-monthly basis.20 The MSWS-12v2 is
completed annually.
First, we compared the psychometric properties of
the MSWS-12v2T with the psychometric properties
of the MSWS-12v2 in the total SWIMS sample.
Second, we examined DIF by comparing item per-
formance of the UK and Turkish versions. DIF is
detailed elsewhere.9,14,2628
In brief, the basic premise for the stable performance
of any MSWS-12v2 item is that for any level of
walking ability, the expected value on the item is
the same regardless of whether people are Turkish
or English. In the analysis we: combined Turkish and
UK MSWS-12v2 data; divided the combined sample
into three similar sized subgroups (class intervals)
with different levels of walking ability (low,
medium, high); and compared the expected item
values for Turkish and UK within each class interval.
A two-way analysis of variance provided a unified
way of quantifying DIF across the groups and across
differing levels of walking disability. To enable a
balanced analysis, we selected a random sample of
UK data the same size as the Turkish sample.
If DIF is detected, an important next step is to deter-
mine if it is real (true-positive differences) or artifi-
cial (false-positive/compensatory differences).14,28
This is achieved by removing items demonstrating
DIF, sequentially and iteratively, and reanalysing the
remaining item set after each removal. This process
continues until a set of items has no DIF.
Finally, we determined the extent to which DIF iden-
tified at the item-level impacts on the overall scale-
level estimates derived from all 12 MSWS-12v2
items. To achieve this, we derived two walking abil-
ity estimates for each person in the Turkish sample:
one estimate that used the item values (calibrations)
derived from the Turkish sample analysis; the other
estimate using the item calibrations derived (and
anchored) from the UK total sample. Differences
between these two walking ability estimates were
examined graphically (scatterplot) and statistically
(paired samples t-test).
Results
Stage 1: development of the MSWS-12v2T
questionnaire
Figures in the Supplementary Material show the final
version of the English MSWS-12v2 (Supplementary
Material, Figure 1), and the translated Turkish
MSWS-12v2T (Supplementary Material, Figure 2).
Stage 2: RMT examination of MSWS-12v2T
questionnaire performance
Sample characteristics. A total of 127 Turkish
people with neurologist-confirmed MS were invited
to complete the MSWS-12v2T once; 98% (n¼ 124)
agreed. Baseline data (Table 1) show the sample was
mostly female, relatively young, with mild-to-mod-
erate disability.
MSWS-12v2T questionnaire performance. Table 2
summarises the RMT analyses numerical results.
Dib et al.
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Scale to sample targeting. Figure 1(a) and (c) shows
the person-item threshold distribution plot. Table 2
shows the numerical values. Targeting was adequate
to make reasonable judgements of scale performance
and person measurement. Specifically, the sample
had MSWS-12v2T measurements (upper histogram
bars, Figure 1(a): approximate range 7 toþ 7
logits) that covered the entire scale range (lower
histogram bars, Figure 1(c): item thresholds approxi-
mate range 4 toþ 5 logits). Figure 1(a) shows that
the sample’s disability distribution was skewed to
the left (less disabled end) of the scale range.
Item and scale performance. Figure 1(b) shows the
response categories for all 12 items worked as
intended. Figure 1(c) shows the continuum mapped
by the 12 items’ thresholds spans a wide range (¼9
logits) with no notable gaps and no notable threshold
bunching. Fit statistics showed only two items had fit
residuals outside the recommended range of 2.5 to
þ2.5 (item 12 and 4; fit residuals2.950 andþ3.198).
There were no statistically significant chi-square
values. Figure 2 shows the item characteristic curves
(ICCs) for a better-fitting (Figure 2(a), item 5) and the
worst-fitting (Figure 2(b), item 4) items. In both graphs,
observed item scores (black dots) adhere closely to
expected item values derived from the Rasch measure-
ment model (grey line). This implied adequate item fit,
and the items formed a statistically cohesive set.
Person and sample measurement. The person
separation index (PSI),9 a reliability statistic, was
high (PSI¼ 0.96). This indicates that the MSWS-
12v2T items successfully separated individuals in
this sample of Turkish people with MS with high
reliability. The fit residual for one person was
marginally out-of-range, indicating that 123/124
people gave valid response patterns to the 12 items.
The RMT findings in this sample support the
MSWS-12v2T’s performance as reliable and valid,
to the extent tested.
Stage 3: examination of the performance stability of
the MSWS-12v2T questionnaire
At the time of analysis, the SWIMS MSWS12v2
dataset contained 4731 questionnaires from 1538
people with MS who had participated for 07
years. To maximise the within- and between-item
comparisons, we used the subset of 3310 records
with complete data (score-able responses to all 12
items) and neither floor (total score of 54¼max-
imum walking disability) nor ceiling (total score of
12¼minimum walking disability) effects.c Table 1
shows the UK and Turkish samples differed notably
in size, age, and MSWS-12v2 score/location
distributions.
Table 2 shows the RMT results for the Turkish and
two UK samples. Results for the random sample
(n¼ 124) that were chosen from the UK sample
(n¼ 3310) are included, to enable a DIF analysis
in samples of similar sizes. The three samples
show similarities and differences. These results are
shown, in part, to illustrate the difficulty of determin-
ing the extent of measurement stability from these
examinations, and why specific detailed tests are
required.
Next, we merged the Turkish (n¼ 124) and UK
(n¼ 124) data from the MSWS-12v2 questionnaire
Table 1. Sample characteristics.
Turkish sample SWIMS sample
n 124 3310
Gender: female, % (n) 72.4 (92) 78.2 (2587)
Age at completion in years: mean (SD) 36.2 (10.0) 52.7 (11.3)
EDSS: mean (SD) 2.68 (1.67) a
MS duration in years: mean (SD) 7.96 (6.06)b 8.98 (9.04)c












EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; MSWS-12v2: 12-item Multiple Sclerosis Walking
Scale version 2; SD: standard deviation; SWIMS: South West Impact of MS study.
aEDSS scores were not collected at the same time as the MSWS-12v2 data; btime since MS diagnosis; cMS duration at
time of joining SWIMS study.
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into a stacked data design (p150151)9 for the DIF
analysis. Table 3 shows the full DIF Table with stat-
istically significant values noted. The results are
derived from three related analyses of variance.
The first analysis  ‘class interval’  examines the
differences between the observed scores and
expected values for three disability class intervals.
The class interval analysis is conducted for each
item in the total sample, and is analogous to the
chi-square test of item fit reported in Table 2.
There were no significant differences between
observed and expected scores for any item.
Table 2. Rasch measurement theory (RMT) summary for study samples.
MSWS-12v2 version and sample
Evaluation Turkish UK random UK total
n 124 124 3310
Scale-to-sample targeting
Item locations
Item location range 2.296 toþ 1.266 3.381 toþ 1.376 2.684 toþ 1.075
Threshold location range 4.165 toþ 5.105 4.530 toþ 4.558 3.681 toþ 4.088
Person locations
Person measure range 6.386 toþ 6.653 5.449 toþ 4.713 4.936 toþ 5.005
Person measure mean (SD) 1.693 (3.046) þ0.3988 (2.7950) þ0.406 (2.511)
No. extreme scores: n (%) 7 (5.6) 0 0
Floor/ceiling effect: n (%)a 2 (1.6)/5 (4) 0 0
Item and scale performance
Thresholds
No items with disordered thresholds 0 of 11 1 of 11 (item 4) 0 of 11
Item fit statistics
Item-person interaction
Item fit residuals, range 2.950 toþ 3.198 2.335 toþ 2.082 12.961 toþ 9.070
Item fit residuals exceeding±2.5 2 (n¼ 1<2.5;
n¼ 1 >þ2.5)
0 10 (n¼ 5<2.5;
n¼ 5 >þ2.5)
Specific items out of range <2.5 (item 12);
>þ2.5 (item 4)
0 <2.5¼ items 7, 8, 9, 11, 12
>þ2.5¼ items 2, 3, 4, 5, 6
Item-trait interaction
Chi square values: range 1.025 to 6.202 0.114 to 3.135 6.219 to 248.692
No. significant chi square valuesb 0 0 8 (all items except
1, 2, 6, 10)
Item bias
Total no. of residual correlations 66 66 66
Range of item residual correlations 0.377 toþ 0.452 0.408 toþ 0.419 0.304 toþ 0.353
Correlations>±0.30;±0.40, n (%) 5 (7.6); 1 (1.5) 4 (6.1); 2 (3.0) 2 (3.0); 0
Person/group measurement
Sample separation by these items
Person separation index (reliability) 0.964 0.961 0.955
Person fit statistics












MSWS-12v2: 12-item Multiple Sclerosis Walking Scale version 2; SD: standard deviation.
aWhere the floor effect equals the maximum possible score (worst disability), and the ceiling effect equals the minimum possible score (least
disability).
bBonferroni adjustment (0.000833 for 12 items (0.01/12)).
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The second analysis  ‘language’  examined the
differences between observed item scores by lan-
guage across the three disability class intervals. Six
items had statistically significant values (items
36, 10, and 11), indicating that for these six
items the observed scores of UK and Turkish
people differed more than is expected by chance.
The third analysis examined the interaction
between class interval and language. There were
no significant differences.
To determine if the observed statistically significant
DIF was real or artificial we first removed item 4 as
it had the largest mean square value (26.48), and re-
ran the DIF analysis for the remaining 11 items.
Subsequently, five items had significant DIF (items
3, 5, 6, 7 and 10). The DIF for item 11 had resolved,
which implied artificial DIF. However, the value for
item 7 (that had not been significant previously) was
now significant. We then removed item 5 as it had
the largest mean square value in the 11-item DIF
1. Made it necessary for you to use support when walking indoors?
In the past two weeks, how much has your MS…
2. Made it necessary for you to use support when walking outdoors?
3. Limited your ability to run?
4. Made standing when doing things more difficult?
5. Limited your ability to climb up and down stairs?
6. Limited your balance when standing or walking?
7. Limited your ability to walk?
8. Increased the effort needed for you to walk?
9. Affected how smoothly you walk?
10. Made you concentrate on your walking?
11.  Limited how far you are able to walk?
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Figure 1. (a) and (c) Matching of scale to sample using the Person-item threshold distribution plot;a (b) the Turkish 12-item
Multiple Sclerosis Walking Scale (MSWS-12v2T) item threshold map showing walking ability measurement range (x-axis) rep-
resented by each item’s response categories.b
aPeople with greater levels of walking ability (less walking disabled) are represented by the bars on the left of the upper orange
histogram, while people with lower ability (more walking disabled) are represented by the bars on the right.
bA person with a walking ability of ‘1’ logit (x-axis) is predicted to score two (¼sometimes limited) on item 1 (use support when
walking indoors) and four (¼quite a bit limited) on item 12 (slowed down your walking).
MS: multiple sclerosis; SD: standard deviation.
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analysis (27.02) and re-ran the analysis in the
remaining 10 items. Three items showed significant
DIF (items 6, 7 and 10). Item 6 then had the largest
mean square (item 6¼ 30.27), was removed, and
the analyses re-run in the remaining nine items.
One item had significant DIF (item 7: mean
square¼ 25.08); item 7 was removed and the
analysis re-run in the remaining eight items. No sig-
nificant DIF was detected (mean squares range:
0.044.70). These findings imply real differences
in the performance of four items (4, 5, 6 and 7)
between Turkish and UK people. Figure 3 shows
the ICCs for the four items with significant DIF,
which analysis indicated was real, not artificial
(items: 4, 5, 6 and 7). For all four items, the blue
Turkish-sample line is above the red UK-sample
line. This means that the Turkish people consistently
perceived themselves to be more disabled on these
four items than UK people.
Figure 4 shows the scatterplot for the Turkish
sample, where walking ability estimates were
derived from the Turkish item calibrations (y-axis)
and also from the UK sample item calibrations
(x-axis). The graph implies estimates were very
similar. We examined the numerical differences
using a paired sample t-test; this indicated significant
group differences (mean difference¼0.29 logits;
SD¼ 0.39 logits; range 0.58 toþ 0.74;
t-value¼8.319; p< 0.001). Finally, we determined
the proportion of individuals for whom the differ-
ence between their two walking-ability estimates dif-
fered by more than 1.96 standard errors of the
difference. No individuals were identified.
Discussion
Our aim was to address an increasingly
common measurement problem: the requirement
for cross-cultural measurement stability of PRO
Table 3. Full results of analysis of differential item functioning by language (UK vs Turkish).
Class interval Language Class interval-by-language
Item Mean sq F-value DF p-value Mean sq F-value DF p-value Mean sq F-value DF p-value
01 1.28425 1.61463 2 0.201228 1.63354 2.05378 1 0.153199 0.60621 0.76216 2 0.467842
02 1.14996 1.41054 2 0.246130 7.79092 9.55635 1 0.002237 1.16293 1.42645 2 0.242296
03 0.66964 0.92724 2 0.397133 9.97659 13.81434 1 0.000256a 0.97047 1.34379 2 0.262917
04 5.28286 3.75173 2 0.024943 26.47503 18.80179 1 0.000020a 1.73514 1.23224 2 0.999999
05 1.0388 0.87949 2 0.416401 19.87031 16.82291 1 0.000058a 0.78291 0.66284 2 0.999999
06 1.96168 1.80541 2 0.166750 16.48036 15.16753 1 0.000129a 0.02517 0.02317 2 0.999999
07 1.00776 1.44869 2 0.237030 6.87275 9.87983 1 0.001895 3.09611 4.45077 2 0.012701
08 2.15863 3.64356 2 0.027695 5.09927 8.60709 1 0.003693 0.20208 0.34110 2 0.711353
09 1.71633 2.35778 2 0.096930 0.93870 1.28952 1 0.257330 0.34178 0.46951 2 0.625910
10 0.05167 0.06517 2 0.936929 17.82597 22.48257 1 0.000002a 0.7908 0.99737 2 0.370451
11 0.94754 1.40917 2 0.246464 9.17388 13.64333 1 0.000280a 0.52767 0.78475 2 0.999999
12 1.51168 2.10711 2 0.123953 2.63287 3.66992 1 0.056657 0.30524 0.42547 2 0.999999
DF: degrees of freedom; sq: square.
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Figure 2. Item characteristic curves for one of the best- ((a); item 5) and one of the worst- ((b); item 4) fitting items. (a) Turkish
12-item Multiple Sclerosis Walking Scale (MSWS-12v2T) item 5: how much has your multiple sclerosis (MS) limited your ability
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Agreement between Turkish person locations derived from Turkish and UK item estimates

















































































Figure 3. Four items exhibiting significant differential functioning. (a) Item 4 (made standing when doing things more difficult);
(b) Item 5 (limited your ability to climb up and down stairs); (c) Item 6 (limited your balance when standing or walking); (d) Item 7
(limited your ability to walk).
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questionnaires. We used a demonstration to illustrate
to clinicians how to approach, identify, investigate
and interpret the findings. These stability investiga-
tions are not widely known because most reports
exist in less clinically accessible specialist measure-
ment literature.14,28 Also, the strengths and
weaknesses of different methods for testing cross-
cultural stability have not been articulated well
enough to clinicians to enable selection of the most
appropriate stability assessment method for their
needs.
Here, we translated a commonly used MS PRO ques-
tionnaire into Turkish, using standard methods and
bilingual MS neurologists. As such, we believe this
version can be considered linguistically equivalent,
although this cannot be formally proven. While the
translated version performed well on psychometric
evaluations, specific analyses identified significant
performance differences between the UK and
Turkish MSWS-12v2 questionnaire for four of
12 items. These item-level differences resulted in
statistically different scale-level walking estimates
for groups, but not for individuals. How this would
influence the results of a clinical trial is unclear, as
the findings are context-dependent.
How can investigators proceed when they find sig-
nificant DIF, given these are post-hoc findings in
clinical trial data? One option is to measure people
using the item calibrations from one language, or
from the overall item calibrations derived from all
languages. However, this option ignores real cross-
cultural differences, generates inaccurate measure-
ments of people, and also misrepresents treatment
effects to an unknown degree. The most
scientifically accurate method of dealing with DIF
is to ‘split’ the items to account for the true identified
differences between cultures.14,28 We leave this
demonstration for another occasion. Ultimately, the
extent to which different approaches affect individ-
ual person measurements and study results can only
be determined by undertaking different analyses and
comparing the findings. It is important to reiterate
that these are within-study empirical findings that
may not be generalisable.
Here, we used RMT as the psychometric paradigm
and show that it enables sophisticated evaluations of
measurement stability not achievable using CTT, the
psychometric paradigm most widely used in health-
care settings. CTT provides a perspective only on the
performance of the translation, rather than a detailed
head-to-head comparison of the item-level perform-
ance. We did not use IRT for specific reasons; the
most important being that two- and three-parameter
IRT models do not enable parameter separation, and
therefore the results are sample-distribution
dependent.29
Examinations of DIF are not esoteric analyses lim-
ited to testing cross-cultural measurement stability.
They have wide applicability when the evaluation of
measurement stability is required. For example, DIF
examinations provide sophisticated and highly
appropriate examination of test-retest reliability,9
unlike CTT assessments, which confound scale and
person (in)stability.9 Similarly, examinations of sta-
bility across genders, treatment arms, off/on treat-
ments and different age or disability groups may
all be important assessments.
We appreciate that sophisticated psychometric
methods are difficult to grasp. However, we suggest
that these psychometric methods are warranted in
state-of-the-art clinical trials that determine treat-
ments for people and expend significant public
funds. We recommend wider application of modern
psychometric methods, like RMT, and routine test-
ing of measurement equivalence in pivotal clinical
trial PRO data. Regulatory and scientific require-
ments justify our perspective.
Our study has limitations. The Turkish sample is
small and we studied only one scale across two lan-
guages. However, we do not think these limitations
detract from the article’s main purpose: to provide
clinicians with the beginnings of an accessible dem-
onstration on how to address, investigate, interpret
and manage measurement equivalence.
An important point raised by a reviewer was: how
many people, and who, are required for an adequate
evaluation of cross cultural stability? There is no
simple answer to the sample size question. There is
no truly meaningful way of computing that number as
multiple factors are at play and the interpretations are
not binary. Naturally, larger samples enable poten-
tially more confident interpretations and more
detailed evaluations. However, small sample ana-
lyses provide information that assists thinking, lar-
gely because the Rasch model’s parameter
separability property discussed before (p.2,
Introduction) enables more stable results than other
sample distribution dependent psychometric para-
digms. Regardless of analytic sample size, we
emphasise a careful and thoughtful clinical consider-
ation of the findings within the frame of reference of
the concept of interest and context of use. The ques-
tion of ‘who’ should be studied is simpler  ideally,
Dib et al.
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people broadly representative of those in whom the
intervention under investigation will be used.
In the article we have discussed real and artificial
DIF, but not uniform and non-uniform DIF: a
reason being that no items demonstrated non-uni-
form DIF. A reviewer asked that we address this.
Figure 3 shows the four items with DIF. For all
items, the two coloured lines are parallel, with one
line consistently (systematically; homogeneously)
above the other, indicating ‘uniform’ DIF across
the continuum. Generally, this is easy to understand
conceptually, and to investigate, explain and
manage. When the coloured lines cross, or join at
one or more points on the continuum, the DIF is
described as non-uniform implying the DIF differs
in magnitude, and perhaps direction, across the con-
tinuum. Non-uniform DIF is much more difficult to
explain  both conceptually and empirically  and
requires a very careful exploration of the data to
provide a coherent explanation and set up any
experiments required to clarify the finding or deter-
mine if it is erroneous.
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Notes
a. A traditional CTT psychometric evaluation includes
examinations of: score distributions, scaling assump-
tions, reliability, validity±responsiveness.
b. Indicators of stability specifically include: item func-
tioning (item mean scores, standard deviations (SDs),
and corrected item-total correlations), scale internal
consistency (Cronbach’s alpha coefficient, homogen-
eity coefficient), and test-retest reproducibility (intra-
class correlations between paired measurement of
individuals).
c. Questionnaires with floor or ceiling scores offer no
between-item comparisons.
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